Which AAV serotypes show the highest tropism for hepatocytes?

A: AAV8 is widely recognized for its high transduction efficiency in hepatocytes. Other candidates like AAV5 and AAVrh10 are also frequently evaluated, as the optimal choice can depend on the specific promoter, payload, and study objectives.

How do you control for pre-existing neutralizing antibodies (NAbs)?

A: For comparative efficacy studies, we recommend screening study cohorts for pre-existing NAbs against all candidate serotypes. This ensures that baseline immunity does not confound the interpretation of transduction efficiency and therapeutic effect.

What are the key readouts for comparing liver-directed efficacy?

A: Primary endpoints include vector genome copy number (VCN) in liver tissue, quantitative analysis of transgene expression (mRNA and protein), and measurement of functional protein activity. Histology is used to confirm cellular localization and assess tissue morphology.

How is non-target tissue biodistribution assessed for liver-tropic AAVs?

A: We use quantitative PCR to determine VCN across a comprehensive panel of tissues. This typically includes the spleen, heart, lungs, kidney, brain, and gonads to build a complete safety and distribution profile for each candidate vector.

Selecting the optimal Adeno-Associated Virus (AAV) serotype is a primary determinant of therapeutic efficacy and safety for liver-directed gene therapies. While theoretical tropism provides a starting point, empirical, head-to-head comparative studies in well-characterized in vivo models are required to generate the definitive data needed to de-risk clinical translation. These studies directly compare transduction efficiency, transgene expression, and biodistribution profiles between lead candidates, enabling data-driven selection of the vector most likely to succeed in human trials.

A vector’s performance is a function of its capsid, promoter, and payload. To isolate the impact of the capsid, we design studies that run parallel cohorts with different serotypes (e.g., AAV8 vs. AAV5 vs. AAV9) delivering an identical genetic payload.

This approach provides direct, empirical data on which serotype achieves the highest level of functional protein expression in the target tissue with the lowest distribution to non-target organs. The results provide the empirical data required for a robust regulatory submission package.

A successful comparative study relies on a suite of robust, quantitative analytical methods to measure vector performance. Our standard study designs incorporate multiple endpoints:

• Vector Biodistribution: Quantitative PCR is used to measure vector genome copy numbers across all relevant tissues. This confirms liver targeting and quantifies the extent of any non-target tissue biodistribution.

• Transgene Expression: We assess both mRNA (RT-qPCR) and protein (Western Blot, ELISA, or IHC) levels in liver tissue to confirm the genetic payload is being transcribed and translated effectively.

• Histology: Microscopic examination of liver tissue provides confirmation of cellular localization, transgene expression patterns, and an assessment of overall tissue health and architecture.

• Biomarker Analysis: Where applicable, we measure relevant functional biomarkers in circulation or tissue to demonstrate that the expressed protein is having the intended physiological effect.

])

The principle of matching serotype to target tissue is fundamental to gene therapy development. For example, research into a systemic metabolic disorder demonstrated that a specific AAV serotype could successfully rescue the disease phenotype by targeting the appropriate tissue (PMID: 34454844). This finding reinforces the strategic importance of empirical testing: the biological outcome is directly linked to the initial vector design choices.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

All in vivo studies are conducted in our GxP-ready facilities spanning over 100,000 square feet. Our study designs are guided by the 3Rs principles (Replacement, Reduction, and Refinement) to ensure the highest standards of animal welfare. This rigorous operational framework has supported our clients in achieving a 100% IND success rate since 2019, providing the quality and reliability needed to advance programs on an 18-24 month IND timeline. The Franklin Biolabs brand was launched in 2024, continuing a legacy of scientific excellence.